lisdexamfetamine dimesylate
NDA- Indications
- ADHD
Company intelligence / Profile preview
New River Pharmaceuticals
Radford, Virginia, United Statessec.gov ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- NDA
01
Overview
New River Pharmaceuticals developed Vyvanse (lisdexamfetamine dimesylate), a next-generation stimulant for ADHD. The company was acquired by Shire plc in April 2007 for $2.6 billion to gain full control of Vyvanse as it entered commercial launch. Clinical results supported its efficacy and differentiated safety profile compared to existing stimulants like Adderall XR[1][4][5].
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules (notably prodrugs; e.g., lisdexamfetamine dimesylate)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Shire plc had been a development and commercialization partner prior to full acquisition; no other major partnerships reported.
Beyond the preview
Go deeper on New River Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on New River Pharmaceuticals.